Description
The
GenCRISPR™ Ultra Cas9 product line provides customers with a selection of
research use, GMP preclinical and GMP compliant Cas9 nucleases. The Cas9
protein can be formed with the guide RNA into a ribonucleoprotien (RNP)
complex. The use of an RNP complex to perform gene editing has been shown to
reduce the challenges encountered with other CRISPR gene editing techniques
such as viral and plasmid delivery. Challenges include off-target effects, cell
viability and trascprition/translational challenges.
GenCRISPR™ Ultra Cas9 is
produced by expression in an E. coli
strain carrying a plasmid encoding the Cas9 gene from Streptococcus pyogenes with an N-terminal nuclear localization
signal (NLS).